ATE237587T1 - 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten - Google Patents

11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten

Info

Publication number: ATE237587T1
Authority: AT; Austria
Prior art keywords: derivatives; dialkylprostaglandin; production; active ingredients; products containing
Prior art date: 1997-02-10

Application number

AT98901576T

Other languages

English (en)

Inventor

Shuichi Ohuchida

Takayuki Maruyama

Original Assignee

Ono Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-10

Filing date

1998-02-10

Publication date

2003-05-15

1998-02-10 Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co

2003-05-15 Application granted granted Critical

2003-05-15 Publication of ATE237587T1 publication Critical patent/ATE237587T1/de

Links

239000004480 active ingredient Substances 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
229940126601 medicinal product Drugs 0.000 title 1
229920000858 Cyclodextrin Polymers 0.000 abstract 1
101150053131 PTGER3 gene Proteins 0.000 abstract 1
206010033645 Pancreatitis Diseases 0.000 abstract 1
108010088540 Prostaglandin E receptors Proteins 0.000 abstract 1
102000008866 Prostaglandin E receptors Human genes 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
208000019423 liver disease Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT98901576T 1997-02-10 1998-02-10 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten ATE237587T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP4157197		1997-02-10
PCT/JP1998/000544 WO1998034916A1 (fr)	1997-02-10	1998-02-10	Derives de 11,15-o-dialkylprostaglandine e, leur procede de production, et medicaments renfermant ceux-ci comme principe actif

Publications (1)

Publication Number	Publication Date
ATE237587T1 true ATE237587T1 (de)	2003-05-15

Family

ID=12612138

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98901576T ATE237587T1 (de)	1997-02-10	1998-02-10	11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten

Country Status (10)

Country	Link
US (1)	US6288119B1 (de)
EP (1)	EP1008588B1 (de)
JP (1)	JP4044967B2 (de)
KR (1)	KR20000070903A (de)
AT (1)	ATE237587T1 (de)
DE (1)	DE69813571T2 (de)
DK (1)	DK1008588T3 (de)
ES (1)	ES2196527T3 (de)
PT (1)	PT1008588E (de)
WO (1)	WO1998034916A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2364948C (en)	1999-03-05	2011-04-26	Duke University	C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en)	1999-08-04	2005-05-17	The Procter & Gamble Company	2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020037914A1 (en)	2000-03-31	2002-03-28	Delong Mitchell Anthony	Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en)	2000-03-31	2002-01-31	Delong Mitchell Anthony	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en)	2000-03-31	2002-11-21	Delong Michell Anthony	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
HUE029417T2 (en)	2002-10-10	2017-02-28	Ono Pharmaceutical Co	Microspheres containing ONO-1301
WO2004032964A1 (ja) *	2002-10-10	2004-04-22	Ono Pharmaceutical Co., Ltd.	アレルギー性疾患治療剤
WO2004074842A2 (en) *	2003-02-24	2004-09-02	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 (prostaglandin e2 ep3)
WO2004089411A1 (ja) *	2003-04-03	2004-10-21	Ono Pharmaceutical Co., Ltd.	脊柱管狭窄症治療剤
WO2005009468A1 (ja)	2003-07-25	2005-02-03	Ono Pharmaceutical Co., Ltd.	軟骨関連疾患治療剤
WO2005053707A1 (ja)	2003-12-05	2005-06-16	Ono Pharmaceutical Co., Ltd.	馬尾神経組織血流増加剤
US7326732B2 (en)	2004-02-12	2008-02-05	Pharmagene Laboratories Limited	EP2 receptor agonists
MY144968A (en) *	2005-04-11	2011-11-30	Xenon Pharmaceuticals Inc	Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) *	2005-04-11	2007-05-16	Xenon Pharmaceuticals Inc	Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
JP5040650B2 (ja)	2005-06-03	2012-10-03	小野薬品工業株式会社	神経再生および／または保護剤
CA2618486A1 (en)	2005-08-09	2007-02-15	Asterand Uk Limited	Ep2 receptor agonists
EP3205644A1 (de)	2005-12-29	2017-08-16	Celtaxsys Inc.	Diaminderivate als inhibitoren der leukotrien-a4 hydrolase
EP2073806B1 (de)	2006-10-12	2012-02-15	Xenon Pharmaceuticals Inc.	Verwendung von spiro-oxindol-verbindungen als therapeutika
WO2008046049A1 (en) *	2006-10-12	2008-04-17	Xenon Pharmaceuticals Inc.	Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
US20090124695A1 (en)	2007-11-14	2009-05-14	Cayman Chemical Company	Prostaglandin e1 and e2 analogs for the treatment of various medical conditions
HRP20150882T1 (hr) *	2008-10-17	2015-09-25	Xenon Pharmaceuticals Inc.	Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
WO2010045197A1 (en) *	2008-10-17	2010-04-22	Xenon Pharmaceuticals, Inc.	Spiro-oxindole compounds and their use as therapeutic agents
US8722739B2 (en)	2008-10-29	2014-05-13	Novaer Holdings, Inc.	Amino acid salts of prostaglandins
US8623918B2 (en)	2008-10-29	2014-01-07	Novaer Holdings, Inc.	Amino acid salts of prostaglandins
TWI437987B (zh)	2009-06-10	2014-05-21	Ono Pharmaceutical Co	具有膀胱排尿肌收縮及尿道括約肌鬆弛之作用的化合物
AR077252A1 (es)	2009-06-29	2011-08-10	Xenon Pharmaceuticals Inc	Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US20110086899A1 (en) *	2009-10-14	2011-04-14	Xenon Pharmaceuticals Inc.	Pharmaceutical compositions for oral administration
PE20170202A1 (es)	2009-10-14	2017-03-24	Xenon Pharmaceuticals Inc	Metodos sinteticos para compuestos espiro-oxoindol
RU2596488C2 (ru)	2010-02-26	2016-09-10	Ксенон Фармасьютикалз Инк.	Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
KR20150002794A (ko)	2012-04-12	2015-01-07	제논 파마슈티칼스 인크.	치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성
DK2891651T3 (en)	2012-08-31	2017-06-06	Ono Pharmaceutical Co	AMINAL SALT AND CRYSTALL THEREOF
AU2014240042C1 (en)	2013-03-14	2019-09-05	Celltaxis, Llc	Inhibitors of leukotriene A4 hydrolase
EP2818484A1 (de)	2013-06-28	2014-12-31	Universitat Autònoma de Barcelona	Synergistische Kombination eines Anti-IgE-Antikörpers und eines EP2-Rezeptoragonisten
AR103636A1 (es)	2015-02-05	2017-05-24	Teva Pharmaceuticals Int Gmbh	Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2017218920A1 (en)	2016-06-16	2017-12-21	Teva Pharmaceuticals International Gmbh	Asymmetric synthesis of funapide
WO2018107158A1 (en)	2016-12-09	2018-06-14	Celtaxsys, Inc.	Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase
CA3045887A1 (en)	2016-12-09	2018-06-14	Celtaxsys, Inc.	Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
US10202362B2 (en)	2016-12-09	2019-02-12	Celtaxsys, Inc.	Inhibitors of leukotriene A4 hydrolase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3835180A (en) *	1971-05-04	1974-09-10	Upjohn Co	15 alkoxy pge compounds
US3876690A (en) *	1973-05-11	1975-04-08	American Cyanamid Co	1-alkoxy-9-keto-prostenoic acid derivatives
GB1451798A (en) *	1973-08-02	1976-10-06	Ici Ltd	Prostanoic acid derivatives
US4236027A (en) *	1977-10-17	1980-11-25	American Cyanamid Company	Novel 11-alkoxy-9-keto (or hydroxy)-prostenoic acid derivatives and method for preparing same
JPS55115836A (en) *	1979-03-02	1980-09-06	Toray Ind Inc	Preparation of methyl ether derivative
DE3510978A1 (de) *	1985-03-22	1986-09-25	Schering AG, Berlin und Bergkamen, 1000 Berlin	Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPH03101622A (ja) *	1989-09-11	1991-04-26	Green Cross Corp:The	肝炎予防治療剤

1998
- 1998-02-10 AT AT98901576T patent/ATE237587T1/de not_active IP Right Cessation
- 1998-02-10 PT PT98901576T patent/PT1008588E/pt unknown
- 1998-02-10 KR KR1019997007168A patent/KR20000070903A/ko not_active Ceased
- 1998-02-10 JP JP53414898A patent/JP4044967B2/ja not_active Expired - Lifetime
- 1998-02-10 DE DE69813571T patent/DE69813571T2/de not_active Expired - Fee Related
- 1998-02-10 US US09/355,626 patent/US6288119B1/en not_active Expired - Lifetime
- 1998-02-10 DK DK98901576T patent/DK1008588T3/da active
- 1998-02-10 ES ES98901576T patent/ES2196527T3/es not_active Expired - Lifetime
- 1998-02-10 WO PCT/JP1998/000544 patent/WO1998034916A1/ja not_active Ceased
- 1998-02-10 EP EP98901576A patent/EP1008588B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1008588A1 (de)	2000-06-14
DK1008588T3 (da)	2003-07-28
ES2196527T3 (es)	2003-12-16
JP4044967B2 (ja)	2008-02-06
WO1998034916A1 (fr)	1998-08-13
DE69813571T2 (de)	2004-02-12
KR20000070903A (ko)	2000-11-25
PT1008588E (pt)	2003-09-30
EP1008588A4 (de)	2000-06-14
DE69813571D1 (de)	2003-05-22
US6288119B1 (en)	2001-09-11
EP1008588B1 (de)	2003-04-16

Legal Events

Date

Code

Title

Description

2003-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1008588

Country of ref document: EP

2005-11-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69813571D1 (de)	2003-05-22	11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
MA27867A1 (fr)	2006-05-02	Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
ATE264337T1 (de)	2004-04-15	Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
CA2333703A1 (en)	1999-12-09	Isothiazole derivatives useful as anticancer agents
NL300175I2 (nl)	2005-05-02	Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
ATE260255T1 (de)	2004-03-15	5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
ATE321543T1 (de)	2006-04-15	Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
MA26725A1 (fr)	2004-12-20	Derives de resorcinol, compositions pharmaceutiques les contenant et procede pour leur preparation
DE60225143D1 (de)	2008-04-03	Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
EP1329218A4 (de)	2007-04-04	Wirkstoffe zur vorbeugung und behandlung portaler hypertonie
DE69600272D1 (de)	1998-06-10	Chinolin-4-carbonylguanidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
AU5879798A (en)	1998-09-08	Agents inhibiting progress of pterygium and postoperative recurrence of the same
DE50204789D1 (de)	2005-12-08	Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
HUP9802897A2 (hu)	2000-11-28	Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
WO2002064552A8 (en)	2002-12-12	1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
ATE19772T1 (de)	1986-05-15	Substituierte alpha-(aethyl)-alpha-(phenyl)-(omega-(dialkylami o)-alkoxy)-benzylalkohole, ihre saeureadditionssalze und quaternaeren salze, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel.
HUP0004900A2 (hu)	2001-06-28	Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények
WO2003080631A3 (en)	2004-04-15	Plasma carboxypeptidase b inhibitors
CA2373962A1 (en)	2000-11-30	Immediate release medicinal compositions for oral use
DK1123937T3 (da)	2004-10-11	Substans GM-95, fremgangsmåde til dets fremstilling samt anvendelse deraf
WO1999058527A3 (en)	2000-01-27	Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
BR0109252A (pt)	2002-12-24	Composto, processo para produzir um composto, composição farmacêutica, e, uso de um composto ou de uma composição
ATE178901T1 (de)	1999-04-15	Anthracyclin-disaccharide, verfahren zu ihrer herstellung, und diese enthaltende arzneimittel
CA2267247A1 (fr)	1998-04-02	Heteroaryloxyethylamines en tant que ligands 5-ht1a
BR9915898A (pt)	2001-08-21	Compostos, composição farmacêutica, e, utilização de um composto